Nalfurafine Hydrochloride

Japan’s intellectual property community recently witnessed a landmark court ruling. On May 27, 2025, the Intellectual Property High Court of Japan issued a judgment in the patent infringement case involving Toray Industries' antipruritic drug Remitch® (Nalfurafine). The court ordered Sawai Group and Fuso Pharmaceutical to pay damages of ¥14.29 billion (~$100 million) and ¥7.47 billion (~$50 million) respectively. The combined total of approximately $150 million marks the highest damages ever awarded in a patent infringement case in Japanese legal history. Case Background: The Tug-of-War over Patent Term ExtensionThe central dispute revolved around Toray's use patent (Patent No. 3531170) for the active ingredient Nalfurafine. Based on the marketing authorization of Remitch® containing Nalfurafine hydrochloride (a salt form), the patent received a five-year Patent Term Extension (PTE), extending its validity until November 21, 2022. In 2018, Sawai and Fuso launched orally disintegrating (OD) tablets of Nalfurafine hydrochloride as generic versions. Toray subsequently filed lawsuits, alleging that its extended patent rights had been infringed. However, the legal battle took multiple twists: ·In March 2021, the Tokyo District Court rejected Toray’s claims, holding that the generics contained Nalfurafine hydrochloride (salt form), which differed from Nalfurafine (interpreted narrowly as the free base) in the original patent. ·Meanwhile, Sawai filed an invalidity challenge against the patent term extension with the Japan Patent Office (JPO), which was initially upheld. ·In a dramatic turn, just five days before the Tokyo ruling, on March 25, 2021, the Intellectual Property High Court overturned the JPO’s decision, recognizing no substantial difference in efficacy between the salt and free forms of Nalfurafine. The 2025 Infringement Judgment by the IP High CourtIn its May 2025 decision, the IP High Court reversed the Tokyo District Court’s ruling and concluded that Sawai’s and Fuso’s generic products did infringe Toray’s extended patent rights. Although the full text of the judgment has yet to be released (as of June 3, 2025), it is expected that the court once again adopted a broader interpretation of “Nalfurafine” to include its hydrochloride salt form. The heart of the controversy lies in the interpretation of Article 68-2 of Japan’s Patent Act, which limits the scope of patent term extensions to products (and specified uses) that are identical to those approved in the original marketing authorization that served as the basis for the extension. In 2017, the IP High Court’s Grand Panel issued its first major interpretation of this clause (Case No. 2016 (Ne) 10046, decided on January 20, 2017), ruling that even if the accused product differs in “ingredient, quantity, dosage and administration, or indication” from the approved product, the PTE will still apply if the differences are minor or formal and the products are essentially the same. However, the precise definition of “essentially the same” remains legally ambiguous. Sawai and Fuso argued that their generics, due to differences in excipients, were not "essentially the same" as Remitch®. They likely asserted that the unique use of excipient combinations, some of which may be patented, placed their products outside the scope of the extended patent. The IP High Court appears to have rejected this line of reasoning, holding that the generics were still essentially the same as Remitch®, despite differences in excipients. Industry Impact: A New Phase in the Originator–Generic Dynamic1. Implications for Originator Companies: ·Strengthens the protection power of the patent term extension system ·Establishes a more rights-holder-friendly standard for infringement determination ·Raises the cost of infringement for generic manufacturers 2. Warnings for Generic Companies: ·Minor changes in formulation or excipients may not suffice to bypass patent protection ·Necessitates more cautious market entry strategies under active PTEs ·May trigger increased licensing negotiations 3. Key Issues to Watch: ·How the judgment defines “essentially the same” in technical and legal terms ·Whether excipient differences will be given more weight in future rulings ·Potential implications for other ongoing PTE-related litigations Global Implications This unprecedented compensation award sends a strong signal and reflects several broader trends: ·Reevaluation of pharmaceutical patent value: As the biopharmaceutical industry evolves, the judiciary is providing stronger protections for high-value patents. ·Need for international alignment: The ruling resonates with similar trends in the U.S. and EU, where courts are increasingly awarding larger damages in IP cases. ·Innovation-driven enforcement: The judgment underscores a judicial commitment to incentivizing R&D through robust patent enforcement. The $150 million damages now serve as a Damocles' sword hanging over generic drug makers in Japan. But where exactly this sword will fall depends on the full reasoning in this and future rulings. As the industry awaits the full text of the judgment, close attention will be paid to the court’s legal interpretation of technical distinctions, which may reshape the future patent landscape for pharmaceuticals in Japan and potentially influence global IP strategies. Discover Eureka LS: AI Agents Built for Biopharma EfficiencyStop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery. ▶ See how 50+ research teams saved 300+ hours/month From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 近日，据NMPA官网公示，郑州泰丰制药提交的4类仿制药玛巴洛沙韦片获批并视同通过一致性评价。该药是一种创新的帽状结构依赖性核酸内切酶抑制剂，原研是由盐野义与罗氏携手研发，是继奥司他韦之后推出的第二种口服抗流感病毒药物。 截图来源：NMPA官网 随着流感季节的再度来临，近期多个流感相关话题频繁占据热搜榜单。其中，因“全病程只需服用一次”的特性，玛巴洛沙韦被视为新一代“流感神药”。玛巴洛沙韦自2021年12月被纳入新版医保目录成为乙类药物以来，该药品的销售增长速度极为迅猛。据摩熵医药数据库显示，2024年（Q1-Q3）玛巴洛沙韦片在全国医院的销售额同比增幅高达406.75%，市场潜力巨大。 截图来源：摩熵医药全国医院销售数据库 截止目前，玛巴洛沙韦片在国内有3家（含原研）药企获批上市。在2022年10月，石药集团欧意药业已经率先获得了玛巴洛沙韦片的上市批准，成为国内首仿。此次，郑州泰丰制药申报的玛巴洛沙韦片获批，为国产第2家，形成“1原研+2国产”格局。此外，在仿制药布局方面，国内仅浙江普利药业1家药企提交了玛巴洛沙韦片4类仿制药的申请，均在审评审批中。 截图来源：摩熵医药中国药品审评数据库 郑州泰丰制药在仿制药领域积极布局，截至目前，郑州泰丰制药提交了8款仿制药上市申请，其中盐酸纳呋拉啡口崩片、甲磺酸溴隐亭片、聚乙二醇4000散(儿童型)3款暂无国内药企获批，若顺利获批，有望拿下国内首仿。 截图来源：摩熵医药中国药品审评数据库 此外，郑州泰丰制药目前已有艾地骨化醇软胶囊、富马酸替诺福韦二吡呋酯片、拉米夫定片、玛巴洛沙韦片4款品种迎来过评。 结语 目前，国内主用的流感抗病毒药物主要有奥司他韦、阿比多尔、玛巴洛沙韦、扎那米韦和帕拉米韦等。流感季节的来临使得玛巴洛沙韦药物备受关注。郑州泰丰制药等国内药企在仿制药研发领域的加速布局，为患者提供了更多选择。未来，随着更多国产仿制药的上市和医保政策的支持，流感治疗领域的市场竞争将更加激烈，同时也将为患者带来更多福音。 END 本文为原创文章，转载请留言获取授权  近期热门资源获取 后台回复关键词“深度报告”，获取价值18600元，报告大礼包 后台回复关键词“2023首仿”，获取2023年首仿药物获批名单 后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。 后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。 后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。 后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。 后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。 后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。 后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。 联系我们，体验摩熵医药更多专业服务 会议 合作 园区 服务 数据库 咨询 定制 服务 媒体 合作 👆👆👆点击上方图片，即可开启摩熵化学数据查询 点击阅读原文，申请摩熵医药企业版免费试用！